Ginkgo biloba extract EGb 761 — Competitive Intelligence Brief

Ginkgo biloba extract EGb 761 (Ginkgo biloba extract EGb 761) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Phytotherapeutic. Area: Neurology.

phase 2 Phytotherapeutic Neurology Small molecule

Target snapshot

Ginkgo biloba extract EGb 761 (Ginkgo biloba extract EGb 761) — VSM Geneesmiddelen b.v.. Ginkgo biloba extract EGb 761 is believed to improve blood flow to the brain by increasing nitric oxide production and reducing platelet aggregation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ginkgo biloba extract EGb 761 TARGET	Ginkgo biloba extract EGb 761	VSM Geneesmiddelen b.v.	phase 2	Phytotherapeutic
Zeller Entspannung film coated tablet	Zeller Entspannung film coated tablet	Max Zeller Soehne AG	marketed	Herbal preparation / Phytotherapeutic agent
Saw Palmetto - weeks 24 - 48	Saw Palmetto - weeks 24 - 48	University of Alabama at Birmingham	phase 3	Phytotherapeutic	5-alpha-reductase
Passiflora ; Crataegus and Salix	Passiflora ; Crataegus and Salix	Marjan Industria e Comercio ltda	phase 3	Herbal combination / Phytotherapeutic agent
Sinupret extract coated tablets	Sinupret extract coated tablets	Bionorica SE	phase 3	Herbal combination / phytotherapeutic agent
Saw Palmetto - first 24 weeks	Saw Palmetto - first 24 weeks	University of Alabama at Birmingham	phase 3	Phytotherapeutic	5-alpha-reductase
Cimicifuga + Hiperico	Cimicifuga + Hiperico	Phytopharm Consulting Brazil	phase 3	Herbal combination / phytotherapeutic agent

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Phytotherapeutic class)

1. University of Alabama at Birmingham · 3 drugs in this class
2. VSM Geneesmiddelen b.v. · 1 drug in this class